NIPH Clinical Trials Search

Basic Information

Recruitment status	recruiting
Health condition(s) or Problem(s) studied	Type 2 diabetes mellitus patients
Date of first enrollment	18/07/2013
Target sample size	200
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : LY2605541 INN of investigational material : insulin peglispro Therapeutic category code : 249 Other hormone preparations (including antihormone preparations) Dosage and Administration for Investigational material : LY2605541 or insulin glargine will be initiated at a dose of 8 units. Following administration of the initial insulin dose, patients will be instructed to administer the insulin subcutaneously once daily at bedtime at approximately the same time every night, using a U100 prefilled pen. The dose will be adjusted using a dosing algorithm based on the patients blood glucose. control material(s) Generic name etc : insulin glargine INN of investigational material : Therapeutic category code : 249 Other hormone preparations (including antihormone preparations) Dosage and Administration for Investigational material : LY2605541 or insulin glargine will be initiated at a dose of 8 units. Following administration of the initial insulin dose, patients will be instructed to administer the insulin subcutaneously once daily at bedtime at approximately the same time every night, using a U100 prefilled pen. The dose will be adjusted using a dosing algorithm based on the patients blood glucose.

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	Not applicable
Gender	Both
Include criteria	Type 2 DM patients at least 20 years of age.
Exclude criteria